PMID- 28445420
OWN - NLM
STAT- MEDLINE
DCOM- 20180221
LR  - 20220317
IS  - 2072-6643 (Electronic)
IS  - 2072-6643 (Linking)
VI  - 9
IP  - 5
DP  - 2017 Apr 26
TI  - Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis 
      with Rheumatoid Arthritis.
LID - 10.3390/nu9050428 [doi]
LID - 428
AB  - The aim of this 12-month retrospective study was to evaluate differences in the 
      outcomes of denosumab alone or denosumab combined with vitamin D and calcium 
      supplementation in patients having osteoporosis (OP) with rheumatoid arthritis 
      (RA). Patients were divided into the denosumab monotherapy group (denosumab 
      group, 22 cases) or denosumab plus vitamin D supplementation group (combination 
      group, 21 cases). We measured serum bone alkaline phosphatase (BAP), N-terminal 
      propeptide of type 1 collagen (P1NP), tartrate-resistant acid phosphatase 
      (TRACP)-5b, and urinary N-terminal telopeptide of type-I collagen (NTX) at 
      baseline, 1 week, and 1, 2, 4, 6, 8, and 12 months. We also assessed bone mineral 
      density (BMD) of the lumbar 1-4 vertebrae (L-BMD) and bilateral total hips 
      (H-BMD) at baseline and 4, 8, and 12 months. Matrix metalloprotanase-3 (MMP-3), 
      Disease Activity Score-28 C-reactive protein (DAS28-CRP), Simplified Disease 
      Activity Index (SDAI), and Health Assessment Questionnaire-Disability Index 
      (HAQ-DI) were assessed before treatment and at 12 months to evaluate RA 
      conditions. The study results showed that BAP, TRACP-5b, and NTX were 
      significantly decreased, but tended to return to pre-treatment levels around 6 
      and 12 months in both groups. While L-BMD and H-BMD substantially increased in 
      both groups, H-BMD had become significantly higher in the combination group at 12 
      months (p < 0.01) as compared with the denosumab group. There were no significant 
      differences between the groups regarding MMP-3, DAS28-CRP, SDAI, or HAQ-DI. 
      Compared with denosumab monotherapy, combination therapy of denosumab with 
      vitamin D and calcium significantly increased H-BMD in patients having OP with 
      RA.
FAU - Nakamura, Yukio
AU  - Nakamura Y
AD  - Department of Orthopaedic Surgery, Shinshu University School of Medicine, Asahi 
      3-1-1, Matsumoto 390-8621, Japan. yxn14@aol.jp.
FAU - Suzuki, Takako
AU  - Suzuki T
AD  - Department of Orthopaedic Surgery, Shinshu University School of Medicine, Asahi 
      3-1-1, Matsumoto 390-8621, Japan. takako1119@shinshu-u.ac.jp.
FAU - Yoshida, Tomohiko
AU  - Yoshida T
AD  - Department of Rheumatology, Toshin Yoshida Internal Medicine, Gomyo 643-2, 
      Sakaki-Machi 389-0606, Japan. yoshidatomohiko@me.com.
FAU - Yamazaki, Hideshi
AU  - Yamazaki H
AD  - Department of Rheumatology, Marunouchi Hospital, Nagisa 1-7-45, Matsumoto 
      390-8601, Japan. yamazaki_h@marunouchi.or.jp.
FAU - Kato, Hiroyuki
AU  - Kato H
AD  - Department of Orthopaedic Surgery, Shinshu University School of Medicine, Asahi 
      3-1-1, Matsumoto 390-8621, Japan. hirokato@shinshu-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20170426
PL  - Switzerland
TA  - Nutrients
JT  - Nutrients
JID - 101521595
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antirheumatic Agents)
RN  - 1406-16-2 (Vitamin D)
RN  - 4EQZ6YO2HI (Denosumab)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - H0G9379FGK (Calcium Carbonate)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/administration & dosage/therapeutic use
MH  - Antirheumatic Agents/administration & dosage/therapeutic use
MH  - Arthritis, Rheumatoid/*complications/drug therapy
MH  - Calcium Carbonate/administration & dosage/*therapeutic use
MH  - Denosumab/administration & dosage/*therapeutic use
MH  - Dietary Supplements
MH  - Female
MH  - Humans
MH  - Methotrexate/administration & dosage/therapeutic use
MH  - Osteoporosis/*complications/*drug therapy
MH  - Prednisolone/administration & dosage/therapeutic use
MH  - Retrospective Studies
MH  - Vitamin D/administration & dosage/*therapeutic use
PMC - PMC5452158
OTO - NOTNLM
OT  - calcium
OT  - denosumab
OT  - osteoporosis
OT  - rheumatoid arthritis
OT  - vitamin D
COIS- The authors have no conflicts of interest to declare.
EDAT- 2017/04/27 06:00
MHDA- 2018/02/22 06:00
PMCR- 2017/05/01
CRDT- 2017/04/27 06:00
PHST- 2017/03/24 00:00 [received]
PHST- 2017/04/16 00:00 [revised]
PHST- 2017/04/21 00:00 [accepted]
PHST- 2017/04/27 06:00 [entrez]
PHST- 2017/04/27 06:00 [pubmed]
PHST- 2018/02/22 06:00 [medline]
PHST- 2017/05/01 00:00 [pmc-release]
AID - nu9050428 [pii]
AID - nutrients-09-00428 [pii]
AID - 10.3390/nu9050428 [doi]
PST - epublish
SO  - Nutrients. 2017 Apr 26;9(5):428. doi: 10.3390/nu9050428.